Results 231 to 240 of about 25,109 (253)
Some of the next articles are maybe not open access.
Medicinal Chemistry Research, 2017
HER3, a member of the human epidermal growth factor receptor family of receptor tyrosine kinases, is a pseudokinase that plays an important role in allosteric activation of other HER receptors. A gatekeeper mutation (T768I) of HER3 abrogates bosutinib binding to the ATP-binding site. This mechanism remains unresolved.
Chun-Ling Dong, Fang-Chun Guo, Jie Xue
openaire +1 more source
HER3, a member of the human epidermal growth factor receptor family of receptor tyrosine kinases, is a pseudokinase that plays an important role in allosteric activation of other HER receptors. A gatekeeper mutation (T768I) of HER3 abrogates bosutinib binding to the ATP-binding site. This mechanism remains unresolved.
Chun-Ling Dong, Fang-Chun Guo, Jie Xue
openaire +1 more source
Computational Biology and Chemistry, 2017
HER3 is an important therapeutic target in cancer treatments. HER3 Nanobodies (Nbs) are a novel class of antibodies with several competitive advantages over conventional antibodies. A peptidomimetic derived from these Nbs can be considered to be a small peptide mimicking some of the molecular recognition interactions of a natural peptide or protein in ...
Z, Pourhashem +4 more
openaire +2 more sources
HER3 is an important therapeutic target in cancer treatments. HER3 Nanobodies (Nbs) are a novel class of antibodies with several competitive advantages over conventional antibodies. A peptidomimetic derived from these Nbs can be considered to be a small peptide mimicking some of the molecular recognition interactions of a natural peptide or protein in ...
Z, Pourhashem +4 more
openaire +2 more sources
Cancer Research, 2009
Abstract Abstract #4040 Although kinase-defective, the role of the HER3 receptor in driving tumor growth through dimerization with other HER family members is well recognized. There is increasing interest in developing therapeutic strategies to interfere with signaling through this receptor, either directly or indirectly ...
A Mukherjee +9 more
openaire +1 more source
Abstract Abstract #4040 Although kinase-defective, the role of the HER3 receptor in driving tumor growth through dimerization with other HER family members is well recognized. There is increasing interest in developing therapeutic strategies to interfere with signaling through this receptor, either directly or indirectly ...
A Mukherjee +9 more
openaire +1 more source
Pharmacology & therapeutics, 2014
The human epidermal growth factor receptor (HER) family members are targeted by a growing numbers of small molecules and monoclonal antibodies. Resistance against the epidermal growth factor receptor (EGFR) and HER2-targeting agents is a clinically relevant problem forcing research on optimizing targeting of the HER family.
Kol A +6 more
openaire +3 more sources
The human epidermal growth factor receptor (HER) family members are targeted by a growing numbers of small molecules and monoclonal antibodies. Resistance against the epidermal growth factor receptor (EGFR) and HER2-targeting agents is a clinically relevant problem forcing research on optimizing targeting of the HER family.
Kol A +6 more
openaire +3 more sources
Nature Medicine, 2007
Non-small-cell lung cancers with activating mutations in the epidermal growth factor receptor develop resistance to tyrosine kinase inhibitors by recruiting the MET receptor kinase to activate HER3 and the PI3K-Akt cell survival pathway.
openaire +1 more source
Non-small-cell lung cancers with activating mutations in the epidermal growth factor receptor develop resistance to tyrosine kinase inhibitors by recruiting the MET receptor kinase to activate HER3 and the PI3K-Akt cell survival pathway.
openaire +1 more source
HER3 expression in cutaneous tumors.
Anticancer research, 2008In order to elucidate the role of the receptor tyrosine kinase HER3, the expression characteristics in different tissues of cutaneous malignancies and in normal skin were compared.In this study HER3 expression was evaluated by RT-PCR analysis and immunohistochemistry from different tissue specimens of cutaneous tumors like nevi, primary malignant ...
Eva, Wimmer +2 more
openaire +1 more source
2003
The present invention relates to a pharmaceutical composition comprising as an active agent an inhibitor of HER3 activity, particularly an anti-HER3-antibody. Further, the use of this composition for the diagnosis, prevention or treatment of hyperproliferative diseases, particularly tumor diseases is disclosed.
openaire +1 more source
The present invention relates to a pharmaceutical composition comprising as an active agent an inhibitor of HER3 activity, particularly an anti-HER3-antibody. Further, the use of this composition for the diagnosis, prevention or treatment of hyperproliferative diseases, particularly tumor diseases is disclosed.
openaire +1 more source
Emerging importance of HER3 in tumorigenesis and cancer therapy
Nature Reviews Clinical OncologyJ. Garrett +4 more
semanticscholar +1 more source